• Alias: MPDL3280A, RO5541267
    • Fully humanized, mAb directed against the protein ligand PD-L1 expressed on activated T cells which, in turn, will enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation.
    • FDA approved for locally advanced or metastatic urothelial carcinoma with PD-L1 expression or metastatic NSCLC
    • Recommended dose: 1,200 mg IV every 3 weeks
    • Half-life: 27 days
    • Common side effects: Peripheral edema, fatigue, skin rash, hyponatremia, decreased appetite, transaminitis, hyperbilirubinemia, infection
    Other topics in Targeted and Immunotherapy Agents